Another study has shown an inverse correlation between MAPK signalling and MYCN status in response to targeted therapy (MEK and CDK4/6 inhibitors) in preclinical models of NB, suggesting that therapy targeting the MAPK pathway could have improved efficacy when MYCN is not amplified83. Here, MAP2K7 is linked to neuroblastoma.